Iqvia Holdings (IQV) Non-Current Deferred Tax Liability (2011 - 2026)
Iqvia Holdings' (IQV) quarterly Non-Current Deferred Tax Liability came in at $173.0 million in Q2 2026, down 19.91% year-over-year from $216.0 million in Q2 2025, and up 8.81% quarter-over-quarter from $159.0 million in Q1 2026.
Analysis
Iqvia Holdings (IQV) Non-Current Deferred Tax Liability (2011 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Non-Current Deferred Tax Liability across 16 years of filings, most recently posting $173.0 million for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability fell 19.91% year-over-year to $173.0 million; the TTM figure through Jun 2026 stood at $173.0 million (down 19.91% YoY), while the FY2025 annual figure was $179.0 million, down 75.78% from the prior year.
- Non-Current Deferred Tax Liability came in at $173.0 million for Q2 2026 at Iqvia Holdings, up from $159.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $976.0 million in Q4 2022 to a low of $128.0 million in Q3 2024.
- Average Non-Current Deferred Tax Liability over 5 years is $373.1 million, with a median of $290.5 million recorded in 2023.
- Year-over-year, Non-Current Deferred Tax Liability surged 88.55% in 2022 and slumped 75.78% in 2025.
- Over 5 years, Non-Current Deferred Tax Liability stood at $976.0 million in 2022, then decreased by 21.52% to $766.0 million in 2023, then decreased by 3.52% to $739.0 million in 2024, then tumbled by 75.78% to $179.0 million in 2025, then dropped by 3.35% to $173.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $173.0 million in Q2 2026, $159.0 million in Q1 2026, and $179.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 173.00 Mn |
| Mar 31, 2026 | 159.00 Mn |
| Dec 31, 2025 | 179.00 Mn |
| Sep 30, 2025 | 207.00 Mn |
| Jun 30, 2025 | 216.00 Mn |
| Mar 31, 2025 | 197.00 Mn |
| Dec 31, 2024 | 739.00 Mn |
| Sep 30, 2024 | 128.00 Mn |
| Jun 30, 2024 | 149.00 Mn |
| Mar 31, 2024 | 164.00 Mn |
| Dec 31, 2023 | 766.00 Mn |
| Sep 30, 2023 | 365.00 Mn |
| Jun 30, 2023 | 367.00 Mn |
| Mar 31, 2023 | 421.00 Mn |
| Dec 31, 2022 | 976.00 Mn |
| Sep 30, 2022 | 560.00 Mn |
| Jun 30, 2022 | 494.00 Mn |
| Mar 31, 2022 | 455.00 Mn |
| Dec 31, 2021 | 1.07 Bn |
| Sep 30, 2021 | 297.00 Mn |